Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population.

Technol Cancer Res Treat · 2022 · PMC9623362 · PMID 36310472

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Based on the data from PALOMA-2/3, HR+/HER2− MBC patients showed a trend of full-line benefit treated with CDK4/6 inhibitor combined with AI/fulvestrant, regardless of the presence of endocrine resistance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.